Abstract #1846
Classification of tumor components based on DCE and DSC data in patients with glioblastoma
Moran Artzi 1,2 , Deborah T. Blumenthal 3 , Felix Bokstein 3 , Guy Nadav 1,4 , Gilad Liberman 1 , Orna Aizenstein 1 , and Dafna Ben Bashat 1,5
1
Functional Brain Center, Tel Aviv Sourasky
Medical Center, Tel Aviv, Israel,
2
Sackler
Faculty of Medicine, Tel Aviv University, Tel Aviv,
Israel,
3
Neuro-Oncology
Service, Tel Aviv Sourasky Medical Center, Tel Aviv,
Israel,
4
Faculty
of Engineering, Tel Aviv University, Tel Aviv, Israel,
5
Sackler
Faculty of Medicine and Sagol School of Neuroscience,
Tel Aviv University, Tel Aviv, Israel
Classification of tumor area is important for therapy
assessment of patients with glioblastoma (GB). In this
study tumor area was classified in sixteen scans (11
patients) using k-mean analyses of DSC and DCE data, (1)
based on group analysis; (2) on individual patient
basis, using cluster's centroid vectors obtained from
the group analysis. Three clusters were identified:
permeable-tumor, infiltrative-tumor and vasogenic-edema,
validated using MRS. A high correlation was obtained
between methods. Five patients were scanned
longitudinally following bevacizumab. Results suggest a
non-enhancing tumor progression pattern following
therapy. This demonstrates the potential of this method
to be used in clinical settings.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.